Enrolment completed – 120 patients with end-stage renal disease in 22 centers in Europe Primary endpoint readouts anticipated in Q2 2025, first market approval expected in 2026 Capability to obtain market approval is further strengthened with the appointment of Rob Eyers as Chief Technology Officer. EINDHOVEN, The Netherlands, 7 January 2025 – Xeltis, a leading […]
Just days after anti-vaxxer Robert F Kennedy Jr was nominated as President-elect Donald Trump’s health secretary, the first case of the mpox strain of most concern to scientists has been recorded in the U.S. While mpox has been declared a global health emergency by the World Health Organization, U.S. public health officials have not seemed […]
Brings over 30 years of experience in cardiovascular clinical research, business development, training, education, and medical affairs Strengthens Xeltis’ leadership team following IDE approval for initiation of US pivotal study for aXessTM, its restorative vascular access conduit EINDHOVEN, The Netherlands, 5 November 2024 – Xeltis, a leading developer of transformative implants that enable the natural […]
Deep expertise in leading drug discovery programs across oncology, neuroscience and epigenetics Will drive advancement of Curve’s rich pipeline of first-in-class therapeutic assets Builds on recent leadership team appointments, including Andre Hoekema as Chair of the Board Southampton, UK, 9 October 2024 – Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company pioneering a […]
Dr Hoekema brings over four decades of successful biotech and life science leadership Dr Cora Griffin appointed to head up business development, follows recent appointment of Simon Jones as CFO/COO New hires to accelerate ambition to turbocharge the discovery platform, develop innovative therapeutic pipeline and expand pharma relationships Southampton, UK, 2 October 2024 – Curve […]
